Pedro Mendes‐Bastos

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 302 citations

Life Sciences, Immunology, Pharmacotherapy +6

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2021 · 116 citations · Full text

Medicine, Dermatology, Immunology +16

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2022 · 75 citations · Full text

Medicine, Dermatology, Immunology +16

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

Amy S. Paller, Barry Ladizinski, Pedro Mendes‐Bastos et al. · JAMA Dermatology · 2023 · 66 citations · Full text

Medicine, Dermatology, Pediatrics +17

<scp>Real‐world</scp> clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study

Kilian Eyerich, Melinda Gooderham, Juan Francisco Silvestre et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 62 citations · Full text

Medicine, Dermatology, Pharmacoeconomics +17